Rumienczyk Izabela, Kulecka Maria, Statkiewicz Małgorzata, Ostrowski Jerzy, Mikula Michal
Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Department of Gastroenterology, Hepatology and Clinical Oncology, Centre for Postgraduate Medical Education, 01-813 Warsaw, Poland.
Biomedicines. 2022 Apr 17;10(4):921. doi: 10.3390/biomedicines10040921.
Sepsis involves life-threatening organ dysfunction caused by a dysregulated host response to infection. Despite three decades of efforts and multiple clinical trials, no treatment, except antibiotics and supportive care, has been approved for this devastating syndrome. Simultaneously, numerous preclinical studies have shown the effectiveness of oncology-indicated drugs in ameliorating sepsis. Here we focus on cataloging these efforts with both oncology-approved and under-development drugs that have been repositioned to treat bacterial-induced sepsis models. In this context, we also envision the exciting prospect for further standard and oncology drug combination testing that could ultimately improve clinical outcomes in sepsis.
脓毒症是由宿主对感染的失调反应引起的危及生命的器官功能障碍。尽管经过三十年的努力和多项临床试验,但除了抗生素和支持性治疗外,尚无针对这种毁灭性综合征的获批治疗方法。同时,大量临床前研究表明,肿瘤学适应症药物在改善脓毒症方面具有有效性。在此,我们重点梳理那些已重新定位用于治疗细菌诱导的脓毒症模型的、已获肿瘤学批准及正在研发的药物的相关研究成果。在此背景下,我们还展望了进一步进行标准化和肿瘤学药物联合测试的令人兴奋的前景,这最终可能改善脓毒症的临床结局。